Abstract
Objective: To understand the clinical value of combined detection of cholyglycine CG and TBA in differential diagnosis of hepatobiliary diseases. Methods: Serum samples from 50 healthy people were collected as healthy control group. According to the latest disease diagnosis and treatment plan, 58 cases of HBV asymptomatic carrier group, 17 cases of viral hepatitis group, 49 cases of cirrhosis group, 50 cases of primary liver cancer group and 50 cases of other hepatobiliary diseases groups were collected respectively. The concentration levels of cholyglycine and total bile acid in each group were detected, and the differences among each group were compared. Results: By statistical analysis, serum CG concentration in viral hepatitis group, cirrhosis group, primary liver cancer group and other hepatobiliary diseases group was significantly higher than that in asymptomatic HEPATITIS B carriers and healthy control group, the differences were statistically significant (p 0.05). There was no significant difference in CG concentration among viral hepatitis group, liver cirrhosis group, primary liver cancer group and other hepatobiliary diseases group (p > 0.05). The serum TBA levels of asymptomatic carriers, viral hepatitis group, cirrhosis group, primary liver cancer group and other hepatobiliary system diseases group were significantly higher than those of healthy control group, the difference was statistically significant, p 0.05. Conclusion: Serum CG expression can not only detect liver lesions, but also distinguish different liver lesions. The positive rate of CG combined with TBA detection in patients with hepatobiliary diseases is significantly higher than that of single CG index detection. CG combined with TBA detection can significantly improve the sensitivity and accuracy of the diagnosis of hepatobiliary diseases, which is worthy of popularization and application.
Highlights
Cholyglycine (CG) is secreted by liver cells and is the main bile acid in serum during the third trimester of pregnancy
It was found that the serum CG levels in the viral hepatitis group, liver cirrhosis group, primary liver cancer group and other hepatobiliary disease groups were significantly higher than those in asymptomatic carriers of hepatitis B virus and healthy controls, and the differences were statistically significant, p < 0.05
There was no significant difference in the concentration of CG among viral hepatitis group, liver cirrhosis group, primary liver cancer group and other hepatobiliary diseases group, p > 0.05
Summary
Cholyglycine (CG) is secreted by liver cells and is the main bile acid in serum during the third trimester of pregnancy. When hepatocytes are damaged or cholestasis occurs, the disorder of Cholyglycinemetabolism is caused, or when hepatocytes are damaged or necrotic, a large amount of glycine enters the peripheral blood, which can increase the content of glycocholic acid in serum [1,2,3]. It can be considered as a sensitive index to indicate the impairment of liver function. In order to understand the clinical application value of the combined detection of cholyglycine CG and TBA in the differential diagnosis of hepatobiliary diseases, this topic will collect the serum of patients with hepatobiliary diseases and healthy controls to detect the serum glycine level alone or jointly, and explore the application value of glycocholic acid in hepatobiliary diseases through statistical analysis
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
